An Investigational Vaccine (pNGVL4a-Sig/E7[detox]/HSP70 and TA-HPV) Prior to Cell Collection in Healthy Haploidentical Stem Cell Transplant Donors

Inclusion Criteria

• Human lymphocyte antigen (HLA)-haploidentical relative of a patient with advanced HPV 16-associated malignancy
• Female or male subjects age 18-70 years of age with a body mass index (BMI) ≥ 18.5 kg/m^2
• Subjects must understand and agree to comply with the requirements of the study and they must be willing and able to provide consent to participate and having signed an informed consent form (ICF) indicating voluntary consent to participate in the study prior to the initiation of screening or study-related activities
• Able and willing to comply with all study procedures
• Must meet at least one of the following three criteria with respect to their reproductive capacity: 1) Post-menopausal as defined by spontaneous amenorrhea for ≥ 12 months; 2) Surgically sterile or have a partner who is sterile (i.e., vasectomy in males or absence of ovaries and/or uterus in females); 3) Use of medically effective contraception with a failure rate of < 1% per year when used consistently and correctly from screening until 3 months following last dose. Acceptable methods include hormonal contraception (including implants or combined oral + injected); two barrier methods (e.g., condom with spermicide and cervical cap); or abstinence when this is the subject’s preferred and usual lifestyle
• Medically healthy with no clinically significant findings in the physical examination, medical history, vital signs
• Normal screening electrocardiogram (ECG) or screening ECG with no clinically significant findings as judged by the investigator
• No history of any clinically significant immunosuppressive or autoimmune disease including hematologic malignancy or history of solid organ or bone marrow transplantation
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• White blood cell count ≥ 3,000
• Lymphocyte number ≥ 500
• Absolute neutrophil count ≥ 1,000
• Platelets ≥ 90,000
• Hemoglobin ≥ 9
• Total bilirubin < 1.5 x upper limit of normal (ULN) (< 3 x ULN if Gilbert’s disease)
• Cardiac troponin < 0.04 ng/mL
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/Alanine aminotransferase(ALT) (serum glutamic pyruvic transaminase [SGPT]) < 3 x ULN
• Creatinine < 1.5 x ULN or estimated creatinine clearance ≥ 60 mL/min per modified Cockroft-Gault formula

Exclusion Criteria

• Prior vaccination with any HPV antigen (prophylactic or therapeutic) except L1. Individuals who have been immunized with licensed prophylactic HPV vaccines (e.g. Gardasil®, Cervarix®) are not excluded
• Subjects who have had chemotherapy, radiation, biological cancer therapy, or other investigational
• Subjects who have had surgery within 28 days of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc.)
• History of myocarditis or pericarditis, or other known underlying heart disease (e.g., cardiomyopathy, congestive heart failure, symptomatic arrhythmia not controlled by medication, unstable angina, history of acute myocardial infarction or cerebrovascular accident within the past 6 months)
• Subjects with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection/sepsis, or psychiatric illness/social situations that would limit compliance with study requirements
• A history of current or recent concurrent malignancy (≤ 5 years) except non-melanoma skin cancer
• Subjects with active or chronic infection of HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV) (tested at baseline)
• Subjects who have an active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus [SLE], ulcerative colitis, Crohn's disease, multiple sclerosis [MS], ankylosing spondylitis) with immunodeficiency as a clinical component
• Subjects treated with immunosuppressive drugs such as cyclosporine, adrenocorticotropic hormone (ACTH), alkylating agents, antimetabolites, radiation, tumor necrosis factor (TNF) inhibitors, or systemic corticosteroids, either chronically or in the past 2 months
• Subjects with a recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; subjects who have acquired, hereditary, or congenital immunodeficiencies
• Subjects and their close social, sexual, or domestic contacts may not have non-healed wounds or active exfoliative skin conditions such as: Eczema, burns, impetigo, varicella-zoster virus infection, herpes simplex virus infection, severe acne, severe diaper dermatitis with extensive areas of denuded skin, psoriasis, lichen planus, Darier disease (keratosis follicularis)
• History or presence of atopic dermatitis
• Conditions associated with immunosuppression such as HIV/AIDS, leukemia, lymphoma, generalized malignancy, solid organ transplant or hematopoietic stem cell transplant recipients
• Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements or assessment of immunologic endpoints
• Prisoners or subjects who are compulsorily detained (involuntary incarceration) for treatment of either a physical or psychiatric illness
• Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the evaluation of any study endpoint
• Women of child-bearing potential who are not on any form of birth control will be excluded
• Breast feeding
• No close social contact with children under 5 years old or close social or domestic contact with a pregnant woman
• Serious vaccine component allergy